Larry Smith

SmithOnStocks publishes reports on biotechnology, medical technology and pharmaceutical companies.

[Larry Smith @SmithOnStocks]

$ CYRX Cryoport: The Bristol-Myers Acquisition of Celgene is a Validation of my Investment Thesis for Cryoport (CYRX, Buy, $9.05) https://t.co/73jQxgsa7a

[Larry Smith @SmithOnStocks]

$PTLA Portola: Tidbits from Presentation at JP Morgan Healthcare Conference (PTLA, Buy, $21.96) https://t.co/76AuWyEbFH

[Larry Smith @SmithOnStocks]

$BMY Negative Market Reaction to Celgene Acquisition is a Buying Opportunity https://t.co/0aybnueJbx

[Larry Smith @SmithOnStocks]

$nwbo $46 million non-dilutive financing provides major boost to investment outlook. See my report. https://t.co/pidvWRoYUR

[Larry Smith @SmithOnStocks]

$cyrx Cryoport raises a $25 million warchest for acquisiitons https://t.co/OyAt5ZlY87

[Larry Smith @SmithOnStocks]

$NWBO I have just publihed a fairly detailed update on my investment thesis that incorporates some thoughts from the recent refreash of blinded data from tjhe phase 3. https://t.co/FlqwOvhLZx

[Larry Smith @SmithOnStocks]

$NWBO Patient demand for DCVax-L under Right to Try law could be overwhelming. Each 100 patients treated could give rise to $25 million of revenues. First treatments likely later this year. See my report https://t.co/KTnOFThGxI

[Larry Smith @SmithOnStocks]

$NWBO Five Spectacular Patient Outcomes for Patients Treated with DCVax-L as Reported at ASCO See the report at this link. https://t.co/QvktwOw3Aj

[Larry Smith @SmithOnStocks]

$nwbo After listening to the testimonials on the webcast, I think that this will go viral and many, many GBM patients will want to get the drug under right to try. Dramatic outcome for metastatic Merckle's cell pt. is amazing. Shows much potential in solid tumors beyond GBM.

[Larry Smith @SmithOnStocks]

$NWBO Right to Try Law Potentially Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L https://t.co/F1Az4pfVGx

[Larry Smith @SmithOnStocks]

@JuliaSkripkaSer What do you know that the 69 authors of the manuscript, who were impressed by the phase 3 interim data, don't know. Why are the two lead investigators, Ashkan and Liau saying that DCVax-L may be a breakthrough for GBM. Just curiious. Maybe they will want to retract the article.

[Larry Smith @SmithOnStocks]

@JohnCendpts Kind of curious why you are sneering at the manuscript and challenging the 69 authors who are very impressed with the data. Lead investigators Ashkan and Liau view this as a potential breakthrough product for GBM. What do you see that they don't. They may want to retract.

[Larry Smith @SmithOnStocks]

@JacobPlieth Kind of curious why you are challenging the 69 authors of the manuscript who are very impressed with the data. Lead investigators Ashkan and Liau view this as a potential breakthrough product for GBM. What do you see that they don't. They may want to retract.

[Larry Smith @SmithOnStocks]

$NWBO Temp website hack resolved. See new rprt Blinded Data from Phase 3 Trial Strongly Suggests that DCVax-L is a Major Advance in the Treatment of Newly Diagnosed Glioblastoma Multiforme; It Looks Like NWBO Has Hit a Therapeutic and Commercial Home Run https://t.co/lfLJmjBe2c

[Larry Smith @SmithOnStocks]

$NWBO New Report Blinded Data from Phase 3 Trial Strongly Suggests that DCVax-L is a Major Advance in the Treatment of Glioblastoma Multiforme; It Looks Like NWBO Has Hit a Therapeutic and Commercial Home Run https://t.co/HpYmUcilAH

[Larry Smith @SmithOnStocks]

$cyrx New detailed sales and earnings model for CYRX https://t.co/nxCRnB0WRI

[Larry Smith @SmithOnStocks]

@KaseyCundy @Protect4us1 @Cernovich @adamfeuerstein @SEC_News The trading desks of the big banks are integrally involved in the naked shorting scheme. There will be lawsuits. AF is really just a stage prop.

[Larry Smith @SmithOnStocks]

$PTLA Why I think that it is probable that AndexXa will be approved on May 4, 2018 PDUFA date https://t.co/U1VUXy7M4g

[Larry Smith @SmithOnStocks]

$NWBO I believe the survival tail of DCVax-L. will be much critical .to regulatory approval than proscribed endpoints of mOS and mPFS. Ten year length of phase 3 will provide unusually powerful insight into survival tail. See https://t.co/ujC7npmeAy for detailed discussion.

[Larry Smith @SmithOnStocks]

$NWBO I have just published a new report called Two Lead Investigators on DCVax-L Phase 3 Trial Believe That It Could be a Major Therapeutic Advance in Treating Glioblastoma Multiforme The link is https://t.co/JNvmSY04Cw